MIKROGEN Acquires Lophius Biosciences To Expand Into T Cell-Based Testing Market
Neuried & Regensburg, Germany, March 08, 2021 – Mikrogen GmbH today announced that it has acquired the assets & technologies of Lophius Biosciences GmbH. Combining Mikrogen’s expertise in diagnostics and automation with Lophius’ technology for pathogen-specific immune stimulation will enable novel diagnostic solutions for infectious diseases and complement the Mikrogen portfolio. Mikrogen will expand operations by taking over the entire Lophius team and Lophius’ laboratories in BioPark Regensburg.
In the future, the Lophius-developed in vitro diagnostic kit T-Track® CMV will be marketed by Mikrogen. By measuring CMV-specific cell-mediated immunity, T-Track® CMV adds an additional dimension to anti-CMV treatment decision-making in transplantation. T-Track® CMV complements the currently used CMV viral load tests, empowering clinicians to make personalized treatment decisions. In addition, Mikrogen will pursue Lophius’ development programs, which include (i) a highly sensitive blood-based next-generation infection detection test that allows to rule-out a tuberculosis (TB) infection early in the diagnostic process, and (ii) a breakthrough solution to reliably differentiate between latent and treatment-requiring active TB infections.
“We are looking forward to welcome on board our new colleagues from Lophius. We believe that bringing together the two teams and their complementary expertise will accelerate our innovative strength to develop new diagnostic solutions, in particular in the area of T cell-based tests to measure the pathogen specific immune status, for immune monitoring and personalized risk stratification. We are really excited to start this journey today,” commented Dr. Erwin Soutschek, CEO & Managing Director of Mikrogen GmbH.
About MIKROGEN GmbH
Mikrogen is a global provider of system solutions for medical laboratory diagnostics. The company´s success factors are the combination of excellent genetic engineering know-how with scientific background and consistent customer orientation. Mikrogen offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogens. The company’s focus is on the serology of bacterial, fungal, parasitic and viral infections as well as on autoimmune and cancer diseases.
Over 30 Years, since 1989, Mikrogen produces antigens for clinical diagnostics. Mikrogen transcends the boundaries of conventional diagnostics and opens up new possibilities for infectious serology with additional confirmation, enabling concrete statements at the time of infection and the stage of the disease. This may provide substantial therapy and support in disease management. Mikrogen's extensive product portfolio covers nearly the entire spectrum of clinical images, such as sexually transmitted diseases and prenatal diagnostics, gastrointestinal infections, respiratory infections, emerging and organ infections, tick / insect borne infections and tropical fever. Mikrogen's automation solutions are comprehensive product lines and can be used modularly within the product lines. The company offers both semi-automatic and fully automatic automation solutions and a very competent service. Mikrogen´s molecular diagnostics for infectious diseases includes both its own highly-qualified and modular product line as well as nucleic acid extraction and a complete MDx workflow, including Extraction, Liquid handling, Amplification and Interpretation.
The highly skilled and experienced employees are the key to the success of Mikrogen. To improve the performance of clinical diagnostics constantly, more than 130 staff members work continuously on the implementation of latest scientific results. Competent consulting and support as well as specialized sales representative make Mikrogen the partner of choice in the diagnostic laboratory.
About Lophius Biosciences GmbH
Lophius Biosciences’ mission is to transform treatment paradigms and patient management with novel molecular diagnostic solutions for life-threatening and highly contagious infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB), a global epidemic affecting hundreds of millions of people. Lophius has developed a proprietary blood-based multi-marker solution, run on widely available platforms, to deliver a significant improvement in TB infection detection over existing approaches. Lophius is advancing biomarker combinations that would disrupt the field by being able to differentiate between active TB disease and latent TB infection. In addition, the company is commercializing a clinically validated CE-marked diagnostic kit (T-Track® CMV) that enables an improved and individualized risk stratification of CMV disease in transplant patients.